(Q34288928)

1 August 2017

1 reference

title

Antiangiogenic agents and their promising potential in combined therapy (English)

1 reference

1 August 2017

main subject

angiogenesis inhibitor

1 reference

Burke PA

1

1 reference

1 August 2017

DeNardo SJ

series ordinal

2

1 reference

1 August 2017

publication date

1 July 2001

1 reference

Critical Reviews in Oncology Hematology

1 August 2017

published in

1 reference

1 August 2017

volume

39

1 reference

1 August 2017

issue

1-2

1 reference

1 August 2017

page(s)

155-171

1 reference

Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

The preclinical evaluation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Anti-angiogenesis: new concept for therapy of solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Vascular Endothelium as the Vulnerable Element in Tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Tumor angiogenesis: past, present and the near future

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Barriers to drug delivery in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Consequences of angiogenesis for tumor progression, metastasis and cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Openings between defective endothelial cells explain tumor vessel leakiness

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

The rationale and future potential of angiogenesis inhibitors in neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Antiangiogenic tumour therapy: will it work?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Angiostatin induces and sustains dormancy of human primary tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Critical determinants of cancer metastasis: rationale for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Tumor Vasculature Targeted Therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

REVIEW: the integrin alpha V beta 3: angiogenesis and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

TNP-470 (AGM-1470): mechanisms of action and early clinical development.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Inhibition of liver metastasis of human gastric carcinoma by angiogenesis inhibitor TNP-470.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Genistein, a dietary-derived inhibitor of in vitro angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Suramin: an anticancer drug with a unique mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Pharmacokinetics of thalidomide in an elderly prostate cancer population

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

The effect of thalidomide on experimental tumors and metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Angiostatin binds ATP synthase on the surface of human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Combined effects of angiostatin and ionizing radiation in antitumour therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Endostatin induces endothelial cell apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Anticancer drug targets: approaching angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Antiangiogenic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Clinical trials of antiangiogenic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Marimastat (BB2516): current status of development

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Rocking the foundations of solid tumor growth by attacking the tumor's blood supply

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

1 reference

7 January 2021

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Definition of Two Angiogenic Pathways by Distinct alpha(v) Integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Vasculogenic mimicry and tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Gene therapy strategies for tumor antiangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

A new era for radiolabeled antibodies in cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900115-9

7 January 2021

10.1016/S1040-8428(01)00115-9

Identifiers

DOI

1 reference

1 August 2017

1 reference